NTLA

Intellia Therapeutics Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↑ 5/10
  • Value↓ 0/10
Intellia Therapeutics sales and earnings growth
NTLA Growth
Neutral
  • Revenue Y/Y↑ 16.92%
  • EPS Y/Y↑ 27.43%
  • FCF Y/Y↓ -11.62%
Intellia Therapeutics gross and profit margin trends
NTLA Profitability
Fair
  • Gross margin ↑ 100.00%
  • EPS margin↓ -609.90%
  • ROIC 5Y↓ -47.24%
Intellia Therapeutics net debt vs free cash flow
NTLA Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Intellia Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗